Kynurenine Attenuates Ulcerative Colitis Mediated by the Aryl Hydrocarbon Receptor

Area of Science:

• Gastroenterology
• Immunology
• Metabolomics

Background:

• Ulcerative colitis (UC) presents a significant health challenge with limited treatment options.
• Existing UC therapies can cause adverse effects, necessitating the search for novel treatments.
• Kynurenine (KYN), a tryptophan metabolite, is explored for its potential therapeutic role in UC.

Purpose of the Study:

• To investigate the efficacy of KYN in ameliorating UC.
• To elucidate the underlying molecular mechanisms by which KYN exerts its effects.
• To assess KYN's impact on intestinal pathology, barrier function, and inflammatory pathways.

Main Methods:

• Evaluation of KYN's effects in a mouse model of colitis.
• Assessment of intestinal pathology, inflammatory cytokines, and tight-junction proteins.
• In vitro studies using lipopolysaccharide (LPS)-stimulated Caco-2 cells to examine KYN's mechanism of action.

Main Results:

• KYN administration significantly relieved UC pathological symptoms in colitis mice.
• KYN improved intestinal barrier function and enhanced Aryl hydrocarbon receptor (AhR) expression.
• KYN inhibited the NF-κB signaling pathway and NLRP3 inflammasome production, dependent on AhR activation.

Conclusions:

• KYN ameliorates UC by enhancing intestinal epithelial barrier function and modulating the AhR-NF-κB-NLRP3 signaling pathway.
• KYN demonstrates potential as a therapeutic agent and dietary supplement for UC management.
• The findings highlight KYN's role in reducing intestinal inflammation and restoring gut barrier integrity.